Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK- 089, a fast skeletal muscle troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase II clinical trial; and aficamten, a novel, oral, small molecule cardiac myosin inhibitor which is in Phase III clinical trial discovered for the treatment of hypertrophic cardiomyopathy. It has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.

Cytokinetics, Incorporated

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cytokinetics (CYTK) and Immunocore Holdings (IMCR)...

Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK) and Immunocore Holdings (IMCR)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Janux Therapeutics Inc (JANX), Cytokinetics (CYTK) a...

Analysts Are Bullish on Top Healthcare Stocks: Janux Therapeutics Inc (JANX), Cytokinetics (CYTK)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on CytomX Therapeutics (CTMX), Cytokinetics (CYTK) and ...

Analysts Offer Insights on Healthcare Companies: CytomX Therapeutics (CTMX), Cytokinetics (CYTK) and Scholar Rock Holding (SRRK)

Insiders have been trading these 5 stocks: (($IRD)), (($CYTK)), (($ACI)), (($WFRD)) and (($PAYS)). Here is a breakdown of their recent trades and t...

Opus, Cytokinetics, Albertsons, Weatherford, Paysign Shock

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cytokinetics (CYTK), RenovoRx (RNXT) and ACADIA Phar...

Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), RenovoRx (RNXT) and ACADIA Pharmaceuticals (ACAD)

Insiders have been trading these 5 stocks: (($TRV)), (($TDG)), (($CYTK)), (($GLBE)) and (($CBIO)). Here is a breakdown of their recent trades and t...

Travelers, TransDigm, Cytokinetics, Global-e, Crescent Shock Moves

In a report released today, Maxwell Skor from Morgan Stanley assigned a Buy rating to Cytokinetics, with a price target of $103.00. Skor covers the...

Cytokinetics (CYTK) Receives a Buy from Morgan Stanley

Bank of America Securities analyst Jason Zemansky maintained a Hold rating on Cytokinetics today and set a price target of $83.00. Zemansky covers ...

Bank of America Securities Keeps Their Hold Rating on Cytokinetics (CYTK)

Insiders have been trading these 5 stocks: (($LRMR)), (($CYTK)), (($ITUB)), (($GLBE)) and (($IMVT)). Here is a breakdown of their recent trades and...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CYTK	$76.76	-5.67%	3.60M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CYTK	$76.76	-5.7%	3.60M
3
4
5
6

CYTK

CYTK

Get Cytokinetics, Incorporated Data in Excel

Get Cytokinetics, Incorporated Data in Excel